Market Access News | pharmaphorum

News

Uplizna is first drug FDA-cleared for rare disease IgG4-RD

Amgen has bagged a second indication for its B cell-depleting therapy Uplizna after the FDA cleared it for rare inflammatory disease IgG4-RD.

News

Germany will reimburse haemophilia gene therapy Hemgenix

Germany has agreed to reimburse CSL Behring's haemophilia B gene therapy Hemgenix with a 'unique' outcomes-based payment model.

News

Novartis gets FDA nod for second of three IgAN drugs

Novartis has claimed accelerated approval in the US for Vanrafia, one of a trio of drugs it hopes will revolutionise the treatment of IgA nephropathy.

News

Pharma in a spin as it tries to gauge Trump tariffs impact

Pharmaceuticals are exempt from the tariffs revealed by President Donald Trump, for now, but the industry is bracing for what may come next.

News

First drug backed for NHS use in untreated Hodgkin lymphoma

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated late-stage Hodgkin lymphoma.

News

President Trump signing an Order at his desk in the Oval Office

Pharma tariffs "will hurt US consumers most of all"

If pharmaceuticals are included in President Trump's 'Liberation Day' tariffs, it is US consumers who will suffer the most, says a new report.

Uplizna is first drug FDA-cleared for rare disease IgG4-RD

Germany will reimburse haemophilia gene therapy Hemgenix

Novartis gets FDA nod for second of three IgAN drugs

Pharma in a spin as it tries to gauge Trump tariffs impact

First drug backed for NHS use in untreated Hodgkin lymphoma

Pharma tariffs "will hurt US consumers most of all"

DNA testing can help right racial imbalance in breast cancer

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks